The state of Missouri currently has 16 active clinical trials seeking participants for Multiple Sclerosis research studies. These trials are conducted in various cities, including Saint Louis, Kansas City, St. Louis and Springfield.
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT03816345
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/17/2025
Locations: Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri +8 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Register for Updates
Smoldering Inflammation in MS
NCT06591429
Recruiting
The goal of this observational study is to learn about inflammation in those with relapsing remitting Multiple Sclerosis (MS). The main questions it aims to answer are: * How does abnormal neural inflammation compare to cellular and molecular inflammation in MS? * Once treated, why does abnormal inflammation persist?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2025
Locations: Barnes Jewish Center for Clinical Imaging Research, St. Louis, Missouri
Conditions: Multiple Sclerosis
Register for Updates
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
NCT04047628
Recruiting
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be followed for 72 months after randomization (Day 0, Visit 0).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/09/2024
Locations: John L. Trotter Multiple Sclerosis Center, Washington University School of Medicine in St. Louis, Saint Louis, Missouri
Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Register for Updates
Functional Outcomes From Diets in Multiple Sclerosis
NCT05327322
Recruiting
The purpose of this study is to test the effects of two dietary interventions, glycemic load and calorie restriction, on physical function, cognition, pain, fatigue, mood, and anxiety in adults with multiple sclerosis (MS). The investigators will also explore the how the diet interventions impact inflammation, immunity, and metabolic biomarkers.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/25/2024
Locations: Washington University, Saint Louis, Missouri
Conditions: Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Register for Updates